Evolus Total Assets 2011-2026 | EOLS

Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.

Main categories of assets
Current assets (used within one year):

Cash and cash equivalents
Accounts receivable (amounts owed by customers)
Inventory of goods, raw materials, and supplies
Short-term investments

Non-current assets (used for more than one year):

Fixed assets (buildings, machinery, equipment)
Intangible assets (brands, patents, software)
Long-term investments
Goodwill (reputational value from mergers)

Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.

Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.

Annual Total Assets Evolus

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
226 M	233 M	189 M	178 M	257 M	209 M	240 M	172 M	152 M	77.5 M	81.3 M	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
257 M	77.5 M	183 M

Quarterly Total Assets Evolus

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
219 M	229 M	213 M	233 M	230 M	234 M	226 M	189 M	168 M	169 M	160 M	178 M	193 M	-	221 M	257 M	215 M	240 M	157 M	209 M	209 M	209 M	209 M	240 M	240 M	240 M	240 M	172 M	172 M	172 M	172 M	152 M	152 M	152 M	152 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
257 M	152 M	201 M

Total Assets of other stocks in the Drug manufacturers industry

Issuer	Total Assets	Price	% 24h	Market Cap	Country
Aerie Pharmaceuticals AERI	431 M	-	-	$ 754 M	USA
Alimera Sciences ALIM	154 M	-	-	$ 142 M	USA
AcelRx Pharmaceuticals ACRX	18.2 M	-	7.5 %	$ 6.35 M	USA
Adamis Pharmaceuticals Corporation ADMP	10.9 M	-	0.86 %	$ 117 M	USA
Agile Therapeutics AGRX	10.3 M	-	10.11 %	$ 58.2 M	USA
Canopy Growth Corporation CGC	918 M	$ 1.08	-0.23 %	$ 116 M	Canada
Cronos Group CRON	1.93 B	$ 2.64	0.57 %	$ 1.37 B	Canada
Catalent CTLT	9.75 B	-	-	$ 11.5 B	USA
Avadel Pharmaceuticals plc AVDL	164 M	-	-	$ 2.06 B	France
China Pharma Holdings CPHI	14.9 M	$ 0.58	-	$ 10.1 M	China
DURECT Corporation DRRX	45.2 M	-	-	$ 50.1 M	USA
Cumberland Pharmaceuticals CPIX	75.6 M	$ 3.74	1.91 %	$ 52.6 M	USA
Eagle Pharmaceuticals EGRX	406 M	-	-39.89 %	$ 27.7 M	USA
Calliditas Therapeutics AB (publ) CALT	1.46 B	-	-0.1 %	$ 2.03 B	Schweden
Endo International plc ENDP	5.14 B	-	-	$ 28.9 M	Irlanda
HEXO Corp. HEXO	681 M	-	2.45 %	$ 38.1 M	Canada
Evoke Pharma EVOK	7.07 M	-	-	$ 36.6 M	USA
Harrow Health HROW	399 M	$ 38.84	-0.97 %	$ 1.43 B	USA
Aurora Cannabis ACB	853 M	$ 3.62	-0.72 %	$ 86.3 M	Canada
Athenex ATNX	204 M	-	-23.39 %	$ 1.76 M	USA
Jupiter Wellness JUPW	7.34 M	-	-	$ 33.6 M	USA
Emergent BioSolutions EBS	1.82 B	$ 8.55	-2.51 %	$ 438 M	USA
Assertio Holdings ASRT	286 M	$ 11.99	-0.66 %	$ 852 M	USA
Bausch Health Companies BHC	27.4 B	$ 5.67	0.8 %	$ 2.07 B	Canada
Lannett Company LCI	484 M	-	1.15 %	$ 7.11 M	USA
Neoleukin Therapeutics NLTX	223 M	-	-	$ 193 M	Canada
OrganiGram Holdings OGI	408 M	$ 1.48	6.47 %	$ 402 M	Canada
Organogenesis Holdings ORGO	498 M	$ 2.92	1.74 %	$ 384 M	USA
Perrigo Company plc PRGO	8.54 B	$ 11.59	-0.86 %	$ 1.61 B	USA
Sundial Growers SNDL	1.35 B	$ 1.55	0.63 %	$ 3.37 M	Canada
TherapeuticsMD TXMD	43.3 M	$ 2.17	0.46 %	$ 22.7 M	USA
ProPhase Labs PRPH	87.6 M	-	-	$ 5.07 M	USA
Veru VERU	60.4 M	$ 2.51	-	$ 339 M	USA
Viatris VTRS	50 B	$ 14.56	-1.05 %	$ 17.5 B	USA
Radius Health RDUS	182 M	-	-	$ 1.42 B	USA
Rockwell Medical RMTI	52.2 M	$ 0.88	-1.56 %	$ 20.5 M	USA
cbdMD YCBD	10.6 M	$ 0.76	-1.04 %	$ 3.28 M	USA
Pacira BioSciences PCRX	1.55 B	$ 23.08	0.96 %	$ 1.07 B	USA
PetIQ PETQ	868 M	-	1.64 %	$ 400 M	USA
OptiNose OPTN	108 M	-	-	$ 1.08 B	USA
PLx Pharma PLXP	76.6 M	-	-27.8 %	$ 2.56 M	USA
Recro Pharma REPH	153 M	-	-4.76 %	$ 65.3 M	USA
Relmada Therapeutics RLMD	97.6 M	$ 4.47	-6.29 %	$ 135 M	USA
SCYNEXIS SCYX	59 M	$ 0.77	-1.29 %	$ 38.4 M	USA
Solid Biosciences SLDB	189 M	$ 5.76	-6.19 %	$ 235 M	USA
Sonoma Pharmaceuticals SNOA	13.7 M	$ 2.77	-1.07 %	$ 3.44 M	USA
Tricida TCDA	169 M	-	-	$ 3.25 M	USA
Tilray TLRY	4.31 B	$ 7.35	0.62 %	$ 4.54 B	Canada
Zynerba Pharmaceuticals ZYNE	55.5 M	-	-	$ 55.5 M	USA